A Prospective, Safety, and Efficacy Clinical Trial of Pressurized Intraperitoneal Aerosol Therapy for Peritoneal Metastasis of Colorectal Cancer

Inclusion Criteria: 1. Patients with peritoneal metastatic adenocarcinoma of colorectal origin, confirmed by histopathology, and without metastasis to other sites. 2. No gender limitation, aged 18 to 75 years old; 3. ECOG score ≤2; 4. Subjects without other malignant diseases; 5. Subjects without laparoscopic surgery contraindications; 6. Expected survival period \> 6 months; 7. Able to comprehend and sign the informed consent form; 8. The function of important organs should meet the following requirements; The absolute neutrophil count (ANC) is ≥1.5×10\^9/L; Platelets ≥ 100×10\^9/L; Hemoglobin ≥8.0g/dl (Note: It is acceptable to achieve hemoglobin ≥8.0g/dl through blood transfusion or other interventions); serum albumin ≥2.8g/dL; Bilirubin ≤1.5 times ULN, ALT and AST ≤1.5 times ULN; if there is liver metastasis, ALT and AST ≤5 times ULN; Creatinine clearance rate ≥50mL/min Exclusion Criteria: 1. Subjects with gastrointestinal obstruction; 2. Subjects who rely entirely on parenteral nutrition; 3. Subjects with decompensated ascites; 4. Subjects with severe abdominal infection (peritonitis); 5. Subjects with extensive abdominal adhesion; 6. Subjects who underwent both tumor reduction surgery and gastrointestinal resection and reconstruction simultaneously; 7. Subjects with portal vein thrombosis; 8. Patients with severe or uncontrolled medical conditions and infections (including atrial fibrillation, angina pectoris, heart failure, ejection fraction less than 50%, refractory hypertension, etc.); 9. Previously allergic to chemotherapy drugs; 10. Individuals with severe heart and lung, liver and kidney, blood system, or mental illnesses, as well as those who abuse drugs; 11. Pregnant or lactating women; 12. Patients who have participated in or are currently participating in other clinical trials within 3 months; 13. Other situations where the researchers believe that the patient is not suitable to participate in this trial; 14. Previously had a history of neurological or psychiatric disorders that would affect study informed consent or follow-up evaluation, such as severe depression or dementia;